Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment with Ipilimumab and Radiation Therapy

Ecaterina Ileana Dumbrava, Veronica Smith, Rasha Alfattal, Adel K. El-Naggar, Marta Penas-Prado, Apostolia M. Tsimberidou

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Immune checkpoint inhibitors such as anti-CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), anti PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death protein-ligand 1) monoclonal antibodies are emerging as standard oncology treatments in various tumor types. The indications will expand as immunotherapies are being investigated in various tumors with promising results. Currently, there is inadequate identification of predictive biomarkers of response or toxicity. Unique response patterns include pseudoprogression and delayed response. The use of immune checkpoint inhibitors exhibit an unique toxicity profile, the immune-related adverse events (irAEs). The most notable immune reactions are noted in skin (rash), gastrointestinal track (colitis, hepatitis, pancreatitis), lung (pneumonitis), heart (myocarditis), and endocrine system (thyroiditis, hypophysitis). We present a patient with metastatic adenoid cystic carcinoma of the left submandibular gland with granulomatous inflammation of the lacrimal glands and axonal neuritis of the cervical and paraspinal nerves following treatment with ipilimumab and radiation therapy.

Original languageEnglish (US)
Pages (from-to)336-339
Number of pages4
JournalJournal of Immunotherapy
Volume41
Issue number7
DOIs
StatePublished - Sep 1 2018

Keywords

  • axonal neuritis
  • granulomatous lacrimal glands inflammation
  • immune checkpoint inhibitors
  • ipilimumab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Autoimmune Granulomatous Inflammation of Lacrimal Glands and Axonal Neuritis Following Treatment with Ipilimumab and Radiation Therapy'. Together they form a unique fingerprint.

Cite this